Glembatumumab vedotin showed in vitro cytotoxicity that was related to GPNMB expression, and it induced complete regressions in GPNMB-expressing melanoma and breast cancer xenografts (93, 95, 96). This evidence concerns the gene GPNMB and breast cancer.